leadf
logo-loader
viewOrthocell Ltd
(
ASX:OCC
)

Orthocell highlights potential for CelGro in treatment of lymphedema

Orthocell Ltd (ASX:OCC)'s Paul Anderson speaks to Proactive after announcing a breakthrough tissue engineering study, combining CelGro® with lymphatic and blood vessel cells to create functional lymphatic tissue, has been published in the Proceedings of the National Academy of Sciences of the United States of America (PNAS). The findings represent a substantial advance in the ex vivo fabrication of implantable lymphatic grafts and their use in novel surgical treatments for patients suffering from lymphedema.

Quick facts: Orthocell Ltd

Follow
ASX:OCC

Price: 0.51 AUD

Market Cap: $97.68 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

Orthocell looks ahead to results from OrthoATI shoulder tendon study in Q4

Orthocell Ltd (ASX:OCC)'s Paul Anderson tells Proactive they've has passed a key milestone by completing the 12-month follow-up of the last patient treated in the Autologous Tenocyte Injection (OrthoATI®) rotator cuff tendon study. The RC study was designed to assess the effectiveness of...

3 weeks, 2 days ago

2 min read